https://orcid.org/0000-0002-2917-9388
References
- Rossignol P, Hernandez AF, Solomon SD, et al. Heart failure drug treatment. Lancet. 2019;393(10175):1034–1044.
- Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol. 2005;46(6):e1–e82.
- New York Heart Association. New York Heart Association (NYHA) classification. NYHA; 1995.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 42(36):3599–3726.
- Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.
- Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25.
- Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.
- Elrabbat MS, Sedrak AS, Elsebaie EH, et al. Cost-Analysis of heart failure cases: a pilot single center study in Egypt. Egypt J Commun Med. 2019;37(1):48–53.
- Hassanin A, Hassanein M, Bendary A, et al. Demographics, clinical characteristics, and outcomes among hospitalized heart failure patients across different regions of Egypt. Egypt Heart J. 2020;72(1):1–9.
- World Health Organization. Global health estimates: Life expectancy and leading causes of death and disability; 2020.
- Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–2312.
- List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657.
- McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
- NICE. Single technology appraisal dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]; 2020. Available from: https://www.nice.org.uk/guidance/ta679/evidence/committee-papers-pdf-9016515613
- World bank website: PPP conversion factor, GDP (LCU per international $) – Egypt, Arab Re. Available from: https://data.worldbank.org/indicator/PA.NUS.PPP?locations=EG
- US Food and Drug Administration. FDA approves new treatment for a type of heart failure; 2020.
- Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation. 2020;141(2):100–111.
- Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020;141(2):90–99.
- NICE. Final appraisal document–Dapagliflozin for treating chronic heart failure with reduced ejection fraction; 2020. Available from: https://www.nice.org.uk/guidance/gid-ta10560/documents/final-appraisal-determination-document
- McEwan P, Darlington O, McMurray JJ, et al. Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF. Eur J Heart Fail. 2020;22(11):2147–2156.
- Savira F, Wang BH, Kompa AR, et al. Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. Eur Heart J. 2020;41(Supplement_2):ehaa946.1051.
- Yao Y, Zhang R, An T, et al. Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Failure. 2020;7(6):3582–3592.
- Hamdy Elsisi G, Nada Y, Rashad N, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt. J Med Econ. 2019;22(2):163–168.